Osteopenia após uso prolongado de acetato de medroxiprogesterona em paciente na menacme
Article Sidebar
Main Article Content
Abstract
Objective: To report and compare contraceptive methods (progestogens), their types and routes of administration, relating them to the incidence of osteopenia. Case details: This is a case report of a 34-year-old patient, under follow-up due to NIC 2/3, with no risk factors for fractures, no comorbidities, and in prolonged use (14 years) of medroxyprogesterone acetate. Due to this fact, osteoporosis was investigated by means of bone densitometry. The densitometry revealed osteopenia, which is mainly due to hypoestrogenism caused by prolonged use of progesterone alone, thus causing a blockage in the axis, taking into account that estrogen has a protective effect on bone mass by inhibiting its reabsorption. Other risk factors also highlighted are lifestyle, such as a sedentary lifestyle and a copious diet. Final considerations: It is considered that the use of isolated progestogens, specifically injectable use, is a major risk factor for the development of osteoporosis. However, the same does not happen with oral progestogens or implants.
Article Details
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
References
2. AMPATZIS C, et al. Effect of oral contraceptives on bone mineral density. Acta Endocrinol (Buchar), 2022; 18(3): 355-360.
3. COMPSTON J, et al. UK clinical guideline for the prevention and treatment of osteoporosis, 2017; 12(1): 43.
4. CRANDALL CJ, et al. Predicting Fracture Risk in Younger Postmenopausal Women: Comparison of the Garvan and FRAX Risk Calculators in the Women's Health Initiative Study. J GenIntern Med, 2019; 34(2): 235-242.
5. DRAGOMAN MV e GAFFIELD ME. The safety of subcutaneous ly administered depot medroxyprogesterone acetate (104mg/0.65mL): A systematic review. Contraception, 2016; 94(3): 202-15.
6. EMENY RT, et al. Association of Receiving Multiple, Concurrent Fracture-Associated Drugs with Hip Fracture Risk. JAMA Netw Open, 2019; 2(11): 1915348.
7. HARA T, et al. Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D. Cochrane Database of Systematic Reviews, 2021; 7: 13424.
8. KIWEEWAMATOVU F. Intramuscular depot medroxyprogesterone acetate accentuates bone loss associated with tenofovir disoproxilfumarate – containing antiretroviral therapy initiation in young women living with HIV (the BONE: CARE study): a prospective cohort study in Uganda. Lancet Glob Health, 2022; 10(5): 694-704.
9. LAM C e MURTHY AS. Depo-Provera (depot medroxyprogesterone acetate) use after bariatric surgery. Open Access J Contracept, 2016; 7: 143-150.
10. NGUYEN PL, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol., 2015; 67(5): 825-36.
11. ORSOLINI LR, et al. Bone impact after two years of low-dose oral contraceptive use during adolescence, PLoS One, 2023; 18(6): 285885.
12. RODEN RC, et al. An exploratory study of depot-medroxyprogesterone acetate and bone mineral density in adolescent and young adult women with cerebral palsy. Contraception, 2020; 101(4): 273-275.
13. SCHINI M, et al. Bone Turnover Markers: Basic Biology to Clinical Applications. Endocr Rev., 2023; 44(3): 417-473.
14. TELLA SH e GALLAGHER JC. Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol, 2014; 142: 155-70.
15. WANG LT, et al. Hormone-Related and Drug-Induced Osteoporosis: A Cellular and Molecular Overview. Int J Mol Sci, 2023; 24(6): 5814.